(Q45414516)

English

Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

scientific article published in June 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

liver cirrhosis

0 references

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

C-H Hung

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

C-M Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

S-N Lu

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

J-H Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

T-H Hu

5

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

H-D Tung

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

C-H Chen

7

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

W-J Chen

8

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

C-S Changchien

9

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

publication date

1 June 2006

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

409-414

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Natural history of hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Factors predictive of a beneficial response to therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Treatment of patients with hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Classification of chronic hepatitis: diagnosis, grading and staging

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00707.X

21 January 2018

Identifiers

10.1111/J.1365-2893.2005.00707.X

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45414516&oldid=2076859534"